Zackary Jones
Family · Prattville, ALNPI 1770039448
Payments from drug & device makers
Across 185 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$554
- GSK$367
- Amgen$331
- Pfizer$270
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$245
- Novo Nordisk$206
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,159100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$121
How this compares
$3,167 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $125,908 |
| EliquisApixaban | 72 | $93,842 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $69,581 |
| MounjaroTirzepatide | 37 | $54,974 |
| JardianceEmpagliflozin | 28 | $32,861 |
| LinzessLinaclotide | 25 | $31,824 |
| Repatha SureclickEvolocumab | 51 | $31,201 |
| Repatha SyringeEvolocumab | 38 | $27,277 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $24,301 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $20,401 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $20,243 |
| TrulicityDulaglutide | 11 | $19,546 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $13,170 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $13,167 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $9,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $206 | $125,90886 claims |
| PfizerEliquis | $270 | $93,84272 claims |
| Lilly USA, LLCMounjaro, Trulicity | $163 | $74,52048 claims |
| GSKTrelegy Ellipta | $367 | $69,58170 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $11 | $46,02840 claims |
| AbbVieLinzess | $554 | $31,82425 claims |
| AstraZenecaBrilinta, Symbicort | $93 | $9,48728 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $4,93511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.
Other family in Prattville
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.